日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Sym004治疗对EGFR靶向治疗产生耐药性且经循环肿瘤DNA分析分子筛选的转移性结直肠癌患者的疗效:一项II期随机临床试验

Montagut, Clara; Argilés, Guillem; Ciardiello, Fortunato; Poulsen, Thomas T; Dienstmann, Rodrigo; Kragh, Michael; Kopetz, Scott; Lindsted, Trine; Ding, Cliff; Vidal, Joana; Clausell-Tormos, Jenifer; Siravegna, Giulia; Sánchez-Martín, Francisco J; Koefoed, Klaus; Pedersen, Mikkel W; Grandal, Michael M; Dvorkin, Mikhail; Wyrwicz, Lucjan; Rovira, Ana; Cubillo, Antonio; Salazar, Ramon; Desseigne, Françoise; Nadal, Cristina; Albanell, Joan; Zagonel, Vittorina; Siena, Salvatore; Fumi, Guglielmo; Rospo, Giuseppe; Nadler, Paul; Horak, Ivan D; Bardelli, Alberto; Tabernero, Josep

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

一种对耐药性 HER2+ 乳腺癌(ERBB 配体过表达)具有高活性的 ERBB1-3 中和抗体混合物

Schwarz, Luis J; Hutchinson, Katherine E; Rexer, Brent N; Estrada, Mónica Valeria; Gonzalez Ericsson, Paula I; Sanders, Melinda E; Dugger, Teresa C; Formisano, Luigi; Guerrero-Zotano, Angel; Red-Brewer, Monica; Young, Christian D; Lantto, Johan; Pedersen, Mikkel W; Kragh, Michael; Horak, Ivan D; Arteaga, Carlos L

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers

Sym004是一种新型抗EGFR抗体混合物,可增强人类肺癌和头颈癌的放射治疗反应。

Huang, Shyhmin; Peet, Chimera R; Saker, Jarob; Li, Chunrong; Armstrong, Eric A; Kragh, Michael; Pedersen, Mikkel W; Harari, Paul M

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.

白细胞介素 21 疗法可增加肿瘤浸润 CD8+ T 细胞的密度,并抑制同源肿瘤的生长

Søndergaard Henrik, Frederiksen Klaus S, Thygesen Peter, Galsgaard Elisabeth D, Skak Kresten, Kristjansen Paul E G, Odum Niels, Kragh Michael